Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorTongji Hospital
About this trial
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.
Eligibility criteria
Qualifiers
Aged between 18 and 75;
achieved complete tumor resection;
histological verification of HCC;
liver function classified as Child-Pugh grade A or B;
Disqualifiers
history of other malignancies or recurrent HCC;
extrahepatic metastasis;
prior treatments for HCC;
ongoing severe postoperative complications;
Trial design
Treatments tested in this trial
- PD-1 Inhibitors
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Tongji Hospital
Lead sponsor
Source ClinicalTrials.gov